Alterity Therapeutics Ltd 6-K, filed Nov 22, 2023
Alterity Therapeutics Ltd (ATHE)
About this 6-K
Alterity Therapeutics Ltd filed this 6-K on November 22, 2023.
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE 13a-16 OR 15d-163
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of November 2023
Alterity Therapeutics Limited
(Name of Registrant)
Level 14, 350 Collins Street, Melbourne, Victoria 3000 Australia
(Address of Principal Executive Office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F ☒ Form 40-F ☐
This Form 6-K is being incorporated by reference into our Registration Statement on Form S-8 (Files No. 333-251073, 333-248980 and 333-228671) and our Registration Statements on Form F-3 (Files No. 333-274816, 333-251647, 333-231417 and 333-250076)
ALTERITY THERAPEUTICS LIMITED
(a development stage enterprise)
The following exhibits are submitted:
| 99.1 | Proposed issue of securities - ATH |
1
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| Alterity Therapeutics Limited | ||
| By: | /s/ Geoffrey P. Kempler | |
| Geoffrey P. Kempler | ||
| Chairman | ||
Date: November 22, 2023
2
Exhibit 99.1
 |
Proposed issue of securities |
| Announcement Summary | |
Entity name
ALTERITY THERAPEUTICS LIMITED
Announcement Type
New announcement
Date of this announcement
22/11/2023
The Proposed issue is:
 | A placement or other type of issue |
Total number of +securities proposed to be issued for a placement or other type of issue
| ASX +security code | +Security description | Maximum
Number of +securities to be issued | ||
| ATH | ORDINARY FULLY PAID | 362,462,762 |
Proposed +issue date
29/11/2023
Refer to next page for full details of the announcement
| Proposed issue of securities | 1/5 |
| | Proposed issue of securities |
Part 1 - Entity and announcement details
| 1.1 | Name of +Entity |
ALTERITY THERAPEUTICS LIMITED
We (the entity named above) give ASX the following information about a proposed issue of +securities and, if ASX agrees to +quote any of the +securities (including any rights) on a +deferred settlement basis, we agree to the matters set out in Appendix 3B of the ASX Listing Rules.
If the +securities are being offered under a +disclosure document or +PDS and are intended to be quoted on ASX, we also apply for quotation of all of the +securities that may be issued under the +disclosure document or +PDS on the terms set out in Appendix 2A of the ASX Listing Rules (on the understanding that once the final number of +securities issued under the +disclosure document or +PDS is known, in accordance with Listing Rule 3.10.3C, we will complete and lodge with ASX an Appendix 2A online form notifying ASX of their issue and applying for their quotation).
| 1.2 | Registered Number Type | Registration Number |
| ABN | 37080699065 | |
| 1.3 | ASX issuer code |
ATH
| 1.4 | The announcement is |
New announcement
| 1.5 | Date of this announcement |
22/11/2023
| 1.6 | The Proposed issue is: |
A placement or other type of issue
| Proposed issue of securities | 2/5 |
| | Proposed issue of securities |
Part 7 - Details of proposed placement or other issue |
|
Part 7A - Conditions |
|
7A.1 Do any external approvals need to be obtained or other conditions satisfied before the placement or other type of issue can proceed on an unconditional basis?
No
Part 7B - Issue details |
|
| Is the proposed security a ‘New class’ (+securities in a class that is not yet quoted or recorded by ASX) or an ‘Existing class’ (additional securities in a class that is already quoted or recorded by ASX)? |
Will the proposed issue of this +security include |
| Existing
class |
No |
Details of +securities proposed to be issued
ASX +security code and description
ATH : ORDINARY FULLY PAID
Number of +securities proposed to be issued
362,462,762
Offer price details
Are the +securities proposed to be issued being issued for a cash consideration?
Yes
| In what currency is the cash consideration being paid? |
What is the issue price per +security? |
| AUD - Australian Dollar |
AUD 0.00350 |
Will these +securities rank equally in all respects from their issue date with the existing issued +securities in that class?
Yes
| Proposed issue of securities | 3/5 |
| | Proposed issue of securities |
| Part 7C - Timetable | |
| 7C.1 | Proposed +issue date |
29/11/2023
Part 7D - Listing Rule requirements |
|
| 7D.1 | Has the entity obtained, or is it obtaining, +security holder approval for the entire issue under listing rule 7.1? |
No
7D.1b Are any of the +securities proposed to be issued without +security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
Yes
7D.1b ( i ) How many +securities are proposed to be issued without security holder approval using the entity’s 15% placement capacity under listing rule 7.1?
| 362,462,762 |
7D.1c Are any of the +securities proposed to be issued without +security holder approval using the entity’s additional 10% placement capacity under listing rule 7.1A (if applicable)?
No
| 7D.2 | Is a party referred to in listing rule 10.11 participating in the proposed issue? |
No
| 7D.3 | Will any of the +securities to be issued be +restricted securities for the purposes of the listing rules? |
No
| 7D.4 | Will any of the +securities to be issued be subject to +voluntary escrow? |
No
Part 7E - Fees and expenses
| 7E.1 | Will there be a lead manager or broker to the proposed issue? |
Yes
| 7E.1a | Who is the lead manager/broker? |
MST Financial Services Pty Ltd
| 7E.1b | What fee, commission or other consideration is payable to them for acting as lead manager/broker? |
6% of amount raised under Placement
| 7E.2 | Is the proposed issue to be underwritten? |
No
| Proposed issue of securities | 4/5 |
| | Proposed issue of securities |
| 7E.4 | Details of any other material fees or costs to be incurred by the entity in connection with the proposed issue |
Part 7F - Further Information
| 7F.01 | The purpose(s) for which the entity is issuing the securities |
The use of proceeds from this financing will provide ongoing funding of Alterity’s Phase 2 clinical trials in MSA, planning for a Phase 3 clinical trial, continuing discovery and research efforts and general working capital. |
| 7F.1 | Will the entity be changing its dividend/distribution policy if the proposed issue proceeds? |
No
| 7F.2 | Any other information the entity wishes to provide about the proposed issue |
7F.3 Any on-sale of the +securities proposed to be issued within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:
The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)
| Proposed issue of securities | 5/5 |